PerMagneUeland Anne-LiseBjørkeMonsen, HelgaRefsum, TrondMarkestad, and CobalaminStatusandItsBiochemicalMarkersMethylmalonicAcidandHomocysteineinDifferentAgeGroupsfrom4Daysto19Years

Fig 1. PTX3 and established markers of disease activity at baseline, 6 weeks and 6 months of treatment. Values are given in median. IRD, inflammatory rheumatic disease; RA,

The macrobiotic infants had very low cobalamin intake (25) and low plasma cobalamin levels combined with several hemato- logic abnormalities (6). In the present

Tracking in skeletal size was robustly established 6–12 months postnatal. Trait ranking at 20 weeks gestation and at birth predicted trait ranking in infancy and explained up to 5%

In a multiple lin- ear regression model adjusting for tHcy, GFR, folate, vitamin B6 and vitamin B12, inflammatory markers neopterin, sCD40L, IL-6 or CRP at 6 months were not

Signs of cell-mediated immune activation, reflected by higher maternal neopterin levels, were observed at 6 weeks postpartum and was associated with markers of a low iron status,

In the present study we have investigated PFAS concentrations in mothers (pregnancy week 18, 28 and 36 and six weeks, four and six months postpartum, n = 114) and in infants at